Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.30 USD
Change Today -0.01 / -0.30%
Volume 21.0K
CRIS On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 9:36 AM 06/2/15 All times are local (Market data is delayed by at least 15 minutes).

curis inc (CRIS) Key Developments

Curis, Inc. Presents Phase 1 Study of CUDC-907 at ASCO Annual Meeting

Curis, Inc. announced that clinical data from two programs will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO), being held from May 29 - June 2, 2015 in Chicago, IL. Curis' study investigators will present data from the Phase 1 study of CUDC-907, Curis' proprietary oral, dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor that is being studied in the ongoing expansion stage of a Phase 1 trial, with a focus on patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The U.S. FDA recently granted Orphan Drug Designation to CUDC-907 for the treatment of DLBCL. Curis is also conducting a separate Phase 1 trial to investigate CUDC-907 in patients with advanced solid tumors, including those with advanced hormone receptor positive breast cancer or with NUT midline carcinoma. In addition, data will be presented from clinical studies of Erivedge, a first-in-class hedgehog pathway inhibitor approved for the treatment of advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.

Curis, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015

Curis, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, Ali Fattaey, Chief Executive Officer, President and Director.

Curis, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Curis, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's total revenue of $1,658,332 compared to $1,284,633 a year ago. Revenues for both periods are comprised solely of royalty revenues recorded on Genentech and Roche's net sales of Erivedge. Loss from operations was $31,021,549 compared to $4,753,343 a year ago. Net loss was $31,848,223 or $0.30 per basic and diluted share compared to $5,563,936,000 $0.06 per basic and diluted share a year ago. The net loss for the current period includes an in-process research and development charge of $24.3 million related to Curis' license agreement with Aurigene.

Curis, Inc. to Report Q1, 2015 Results on May 07, 2015

Curis, Inc. announced that they will report Q1, 2015 results at 9:00 AM, Eastern Standard Time on May 07, 2015

Curis, Inc., Q1 2015 Earnings Call, May 07, 2015

Curis, Inc., Q1 2015 Earnings Call, May 07, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRIS:US $3.29 USD -0.02

CRIS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ArQule Inc $1.82 USD +0.02
CTI BioPharma Corp $2.17 USD 0.00
Cytokinetics Inc $6.14 USD -0.142
Exelixis Inc $3.38 USD -0.06
Navidea Biopharmaceuticals Inc $1.31 USD -0.03
View Industry Companies
 

Industry Analysis

CRIS

Industry Average

Valuation CRIS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 35.6x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 29.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CURIS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.